A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
||Eli Lilly and Company
||Male and Female Patients
|U.S. Govt. ID:
||Ryan Shelton: 212-304-5485 / email@example.com
The purpose of this study is to find out how safe study drug olaratumab given with gemcitabine and docetaxel is for patients and whether olaratumab given with gemcitabine and docetaxel can help patients with advanced or metastatic soft tissue sarcoma (STS).
This study is closed
Gary Schwartz, MD
|Have you been diagnosed with Soft Tissue Sarcoma?